Cancel
OK

You have successfully logged out.

Hello !
chevron_right My profile
chevron_right To My B. Braun overview
Logout

No content results match your keyword.

Content

    No product results match your keyword.

    Products

      Lipofundin® and Lipidem® emulsion for infusion

      A source of parenteral macronutrient fats

      Lipofundin® and Lipidem® provide the macronutrient component in parenteral nutrition regimens. These lipids or fats are a source of energy and are important for absorbing fat-soluble vitamins.


      As the innovator of the proven medium chain triglyceride / long chain triglyceride technology, improving patient outcomes is always our focus. Our products can be tailored and adapted to individual patient needs

      Health Care Professional Check

      By clicking 'Confirm” you declare that you are a health care professional. If you are a member of the public, we will redirect you to the pages dedicated to you.

      Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional.

      B. Braun’s second-generation lipid
      Lipofundin®

      In 1998, B. Braun launched our second-generation lipid: Lipofundin® MCT/LCT. The solution is a physical emulsion mix derived from 50% MCT from Coconut Oil and 50% LCT (EFAs*) from Soya Bean Oil.

      Our lipid emulsion ensures the supply of essential fatty acids as part of complete parenteral nutrition when oral or enteral nutrition is impossible, insufficient, or contraindicated.

      Indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition.

      *EFA - Essential Fatty Acid

      Benefits of MCT/LCT over LCT

      Clinical benefits when comparing MCT/LCT to 100% LCT:

      • Reduction in post-operative mortality in a sub-group of malnutrition surgical patients without cancer (n=22)2
      • Reduction in post-operative intra-abdominal abscesses in surgical patients (n=22)2
      • The ability to eliminate MCT/LCT was not impaired in cirrhotic patients.
      • Lower levels of plasma bilirubin in in-patients4 and improvements in liver function tests in home patients with inflammatory bowel disease1
      • No adverse cardiopulmonary effects were seen when MCT/LCT was given following valvular heart surgery5
      • Significantly shorter weaning period from mechanical ventilation vs LCT in COPD patients with acute respiratory failure6
      • No significant reduction in neutrophil bacterial killing function7
      • Improvement in nitrogen balance in critically ill patients (n=20)8
      • Greater physicochemical stability9

      3-Chamber Bags

      B. Braun’s 3-Chamber Bags incorporate our lipid emulsions, Lipofundin® and Lipidem®. Explore the features of our lipid in parenteral nutrition admixture.

      Convenience bags
      lipid-emulsions-200mg.png

      B. Braun’s third-generation lipid
      Lipidem®

      In 2005, B. Braun launched Lipidem®, our third-generation MCT/LCT lipid emulsion containing Omega-3-Acid triglycerides from fish oil. Omega-3-acid-triglycerides from fish oil, containing high levels of EPA* and DHA**, may have positive effects on diseases such as hypertension, arthritis, atherosclerosis, depression, adult-onset diabetes mellitus, myocardial infarction, thrombosis and some cancers10. Both EPA and DHA are fundamentally important fatty acids and known factors which influence the pattern of inflammation regulating eicosanoids and cytokines11.

      Licensed from pre-term neonates to adults, Lipidem® is suitable for peripheral venous administration and can also be administered separately via peripheral veins as part of total parenteral nutrition

      Indicated for supply of energy, including a readily utilisable lipid component (MCT) and essential omega-6 fatty acids and omega-4 fatty acids, as part of parenteral nutrition when oral or enteral nutrition is impossible, insufficient or contraindicated

      *EPA – Eicosapentaenoic Acid
      **DHA – Docosahexaenoic Acid

      • 0%

        Coconut Oil

        Medium-chain triglycerides

        Source of readily available energy

      • 0%

        Soya Bean Oil

        Long-chain triglycerides

        Source of EFA’s (essential fatty acids) and energy

      • 0%

        Omega-3-Acid Triglycerides

        From fish oil for the delivery of EPA and DHA

      Third-generation lipid in clinical settings

      There are multiple benefits of using MCT/LCT with Omega-3-Acid triglycerides from fish oil. The combination of MCT/LCT with Omega-3-Acid triglycerides from fish oil has shown an improvement in gas exchange in septic patients in the ICU, when compared with MCT/LCT on its own12. ICU patients experienced a reduced risk of nosocomial infections when there was involvement of Omega-3 with MCT/LCT13 when compared with a fish oil free lipid.

      Using Omega-3 with MCT/LCT led to the duration of hospital stays in patients requiring prolonged parenteral nutrition undergoing abdominal surgery, decrease when compared to 100% LCT14. 

      Lipid Emulsion for Infusion Portfolio

      Discover Lipofundin® and Lipidem®

      Single Nutrients
      Related Information

      Access the Lipofundin®, Lipidem® and Omeflex® special Prescribing Information via the links below

      Interested?


      Get in touch with one of our team

      Contact Us

      XX-WEBLE-05-24 

      Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to B. Braun Medical Ltd (0800 298 0299). 

      XX-WEBNT-05-24

      References

      1. Y.A. Carpentier, V. SIderova, J. Bruyns, M. Rubin Long-Term PN and Liver Dysfunction Clinical Nutrition 9 1989;31:31
      2. T. Grau, J. Carlos Ruiz de Adana, S. Zubillaga, S. Fuerte, C. Giron. Randomized Study of Two Different Fat Emulsions in Total Parenteral Nutrition of Malnourished Surgical Patients: Effect on Infectious Morbidity and Mortality Nutr Hosp 2003;18:159-166
      3. S.T. Fan, J. Wong. Metabolic Clearance of a Fat Emulsion Containing Medium-Chain Triglycerides in Cirrhotic Patients. Journal of Parenteral and Enteral Nutrition 1992;16(3):279-283
      4. A.R. Dennison, M. Ball, L.J. Hands, P.J. Crowe, R.M. Watkins, M. Kettleworth. Total Parenteral Nutrition using Conventional and medium Chain triglycerides: Effect on Liver Function tests, Complement, and Nitrogen and Enteral Nutrition 1988;12(1):15-19
      5. F. Fiaccadori, G. Tortorella, G.L. Gonzi, C. Beghi, D. Albertini, S. Pincolini, L. Belli, A. Avogaro. Hemodynamic and respiratory effects of medium-chain and long-chain triglyceride fat emulsions: a prospective randomized study. Rivista Italiana di Nutrizione Parenterale ed Enterale 1997;15(1):6-14
      6. G. Iovinelli, F. Marinaangeli, A. Ciccone, A. Ciccozzi, m. Leonardis, A. Paladini, G. Varrassi. Parenteral nutrition in ventilated patients with chronic obstructive pulmonary disease: long chain vs medium chain triglycerides. Minerva Anestesiol 2007;73:65-76
      7. Dan L Waitzberg, Raquel Bellinati-Pires, Maristela M Salago, Iara P Hypolito, Gloria MDD Colleto, Osmar Yagi, Elisa M Yamamuro, Joaquim Gama-Rodrigues, Henrique W Pinotti. Effect of Total Parenteral Nutrition with Different Lipid Emulsions on Human Monocyte and Neutrophil Functions. Nutrition 1997;13:128-132
      8. M.J. Ball. Parenteral nutrition in the critically ill: use of a medium chain triglyceride emulsion. Intensive Care Medicine 1993;19:89-95
      9. David F. Driscoll, Marc N. Bacon, Bruce R. Bistrian Physicochemical stability of two Types of Intravenous Lipid Emulsion as Total Nutrient Admixtures Journal of Parenteral and Enteral Nutrition 2000;24(1):15-22
      10. L.A. Horrocks, Y.K. Yeo. Health benefits of docosahexanoic acid (DHA) Pharmacol. Res. 1999;40(3):211-225
      11. Pierre Singer, Mette M. Berger, Greet Van den Berghe, Gianni Biolo, Philip Clader, Alastair Forbes, Richard Griffiths, Georg Kreyman, Xavier Leverve, Claude Pichard, ESPEN Guidelines on Parenteral Nutrition: Intensive Care, Clinical Nutrition 2009;28:387-400
      12. Vera M. Barbosa, Elizabeth E. Miles, Conceicao Calhua, Estevao Lafuente, Philip C. Calder. Effects of a fish oil containing lipid emulsion on plasma phospholipid fatty acids, inflammatory markers, and clinical outcomes in septic patients: a randomized, controlled clinical trial. Critical Care 2010;14:R5
      13. Grau-Carmona T, Bonet-Saris A, Garcia-de-Lorenzo A, Sanchez-Alvarez C, Rodriguez-Pozo A, Acosta-Escribano J, Minambres E, Herrero-Masesguer JI, Mesejo A ; Influence of n-3 Polyunsaturated Fatty Acids Enriched Lipid Emulsions on Nosocomial Infections and Clinical Outcomes in Critically Ill Patients: ICU Lipids Study; Crit Care Med. 2015 Jan; 43(1):31-9
      14. Matthias W. Wichman, Paul Thul, Hans-Dieter Czarnetzki, Bart J. Morlion, Matthias Kemen, Karl-Walter Jauch. Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial. Critical Care Medicine 2007;35(3):700-706

      Stay connected with My B. Braun

      Register or login below to access your personalised account, with applications and content tailored specifically to you and your speciality.

      person_outline My B. Braun